Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Randomized Experiments01:13

Randomized Experiments

8.5K
The randomization process involves assigning study participants randomly to experimental or control groups based on their probability of being equally assigned. Randomization is meant to eliminate selection bias and balance known and unknown confounding factors so that the control group is similar to the treatment group as much as possible. A computer program and a random number generator can be used to assign participants to groups in a way that minimizes bias.
Simple randomization
Simple...
8.5K
Bioequivalence Experimental Study Designs: Completely Randomized and Randomized Block Designs01:20

Bioequivalence Experimental Study Designs: Completely Randomized and Randomized Block Designs

43
Body:Bioequivalence experimental study designs are crucial methodologies used in evaluating and comparing the bioavailability of different drug products. These designs are categorized into various types: completely randomized, randomized block, repeated measures, cross and carry-over, and Latin square designs.Completely randomized designs involve randomly allocating treatments to all subjects participating in the experiment. This allocation is achieved by assigning unique random numbers to...
43
Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs01:15

Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs

47
Body:Bioequivalence experimental study designs play a pivotal role in testing the effectiveness of various treatments. Key among these are the repeated measures, cross-over, carry-over, and Latin square designs. In the repeated measures design, each subject receives all treatments, allowing for temporal comparisons. This type of design is useful in reducing variability but requires careful planning to avoid bias.The cross-over design, an economical method, involves sequential administration of...
47
Group Design02:01

Group Design

9.9K
The most basic experimental design involves two groups: the experimental group and the control group. The two groups are designed to be the same except for one difference— experimental manipulation. The experimental group gets the experimental manipulation—that is, the treatment or variable being tested—and the control group does not. Since experimental manipulation is the only difference between the experimental and control groups, we can be sure that any differences between...
9.9K
Blinding01:11

Blinding

3.6K
Blinding is a commonly used method of not telling participants which treatment a subject is receiving. Blinding is a critical part of a randomized control trial or RCT. It reduces the bias that affects the results. In an RCT, blinding is used in the form of a placebo. A placebo effect occurs when untreated subjects falsely believe they have received the treatment and report improved symptoms. A placebo or a dummy treatment is administered to subjects to negate the bias caused by such an effect.
3.6K
Accuracy and Errors in Hypothesis Testing01:13

Accuracy and Errors in Hypothesis Testing

401
Hypothesis testing is a fundamental statistical tool that begins with the assumption that the null hypothesis H0 is true. During this process, two types of errors can occur: Type I and Type II. A Type I error refers to the incorrect rejection of a true null hypothesis, while a Type II error involves the failure to reject a false null hypothesis.
In hypothesis testing, the probability of making a Type I error, denoted as α, is commonly set at 0.05. This significance level indicates a 5%...
401

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lactate-fueled H3K18 lactylation sustains ΔNp63α-dependent self-renewal in limbal epithelial stem cells.

The Journal of biological chemistry·2026
Same author

Synergy Area With FDR-Controlled Evaluation (SAFE) to Robustly Assess Safety Profile in Clinical Trials.

Statistics in medicine·2026
Same author

An enhanced exact permutation rank-based inferential seamless phase 2/3 design.

Journal of biopharmaceutical statistics·2026
Same author

Accelerating medicines to patients: A Bayesian quantitative evidence-based decision-making framework with interim monitoring.

Contemporary clinical trials·2026
Same author

Lutikizumab in Adults With Moderate to Severe Hidradenitis Suppurativa After Anti-TNF Therapy Failure: A Phase 2 Randomized Clinical Trial.

JAMA dermatology·2026
Same author

Upadacitinib Maintenance Therapy in Crohn's Disease: Final Results From the Randomized Phase 3 U-ENDURE Study.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2025
Same journal

Latent Class Log-Linear Models for Estimating Diagnostic Test Accuracy Without a Gold Standard: A Simulation Study.

Statistics in medicine·2026
Same journal

Interpretable Bayesian Modeling for Multireader Multicase Studies: Addressing Overdispersion and Limited Sample Size in Diagnostic Enhancement Evaluation.

Statistics in medicine·2026
Same journal

Adaptive Sequential Multiple Hypotheses Testing for Concomitant Vaccine Safety Surveillance.

Statistics in medicine·2026
Same journal

Novel Distance Regression for Repeated Outcomes With Missing Data: Applications to Longitudinal and Crossover Studies of Microbiome Beta-Diversity.

Statistics in medicine·2026
Same journal

Optimal Weighted Tests for Replication Studies and the 'Two-Trials Rule' With Multiple Hypotheses.

Statistics in medicine·2026
Same journal

Identifiable Copula-Double-Cox Models: A Fully Parametric Framework for Dependent Right-Censored Survival Data.

Statistics in medicine·2026
See all related articles

Related Experiment Video

Updated: Nov 2, 2025

A Modified Lean and Release Technique to Emphasize Response Inhibition and Action Selection in Reactive Balance
07:19

A Modified Lean and Release Technique to Emphasize Response Inhibition and Action Selection in Reactive Balance

Published on: March 19, 2020

6.1K

A practical response adaptive block randomization (RABR) design with analytic type I error protection.

Tianyu Zhan1, Lu Cui2, Ziqian Geng1

  • 1Data and Statistical Sciences, AbbVie Inc., North Chicago, Illinois, USA.

Statistics in Medicine
|June 10, 2021
PubMed
Summary
This summary is machine-generated.

Response adaptive randomization (RAR) improves clinical trials by assigning more patients to effective treatments. A new Response Adaptive Block Randomization (RABR) design offers better control and power for drug development.

Keywords:
confirmatory adaptive designmulti-arm studiessample sizetype I error rate controlunweighted statistics

More Related Videos

Efficient Sampling of Genetically Encoded Biosensor Design Space Enabled with a Design of Experiments and Automation Workflow
09:05

Efficient Sampling of Genetically Encoded Biosensor Design Space Enabled with a Design of Experiments and Automation Workflow

Published on: October 17, 2025

132
Irrelevant Stimuli and Action Control: Analyzing the Influence of Ignored Stimuli via the Distractor-Response Binding Paradigm
12:12

Irrelevant Stimuli and Action Control: Analyzing the Influence of Ignored Stimuli via the Distractor-Response Binding Paradigm

Published on: May 14, 2014

10.8K

Related Experiment Videos

Last Updated: Nov 2, 2025

A Modified Lean and Release Technique to Emphasize Response Inhibition and Action Selection in Reactive Balance
07:19

A Modified Lean and Release Technique to Emphasize Response Inhibition and Action Selection in Reactive Balance

Published on: March 19, 2020

6.1K
Efficient Sampling of Genetically Encoded Biosensor Design Space Enabled with a Design of Experiments and Automation Workflow
09:05

Efficient Sampling of Genetically Encoded Biosensor Design Space Enabled with a Design of Experiments and Automation Workflow

Published on: October 17, 2025

132
Irrelevant Stimuli and Action Control: Analyzing the Influence of Ignored Stimuli via the Distractor-Response Binding Paradigm
12:12

Irrelevant Stimuli and Action Control: Analyzing the Influence of Ignored Stimuli via the Distractor-Response Binding Paradigm

Published on: May 14, 2014

10.8K

Area of Science:

  • Clinical Trials Methodology
  • Biostatistics
  • Drug Development

Background:

  • Response adaptive randomization (RAR) ethically and methodologically benefits clinical trials by allocating patients to superior treatments.
  • RAR complexity and lack of randomization ratio control limit its use in multi-arm confirmatory drug trials.

Purpose of the Study:

  • To introduce a novel Response Adaptive Block Randomization (RABR) design for clinical trials.
  • To enable prespecified randomization ratios for control and high-performing arms.
  • To address limitations of existing RAR methods in complex trial settings.

Main Methods:

  • Proposed a Response Adaptive Block Randomization (RABR) design.
  • Demonstrated validity of the unweighted test with controlled Type I error rate using a weighted combination test.
  • Utilized statistical simulations and a practical clinical trial example for evaluation.

Main Results:

  • The RABR design allows flexible control over randomization ratios.
  • Validated the statistical integrity of the RABR design, maintaining controlled Type I error rates.
  • RABR robustly achieves target sample sizes and enhances statistical power compared to Doubly Adaptive Biased Coin Design.

Conclusions:

  • The proposed Response Adaptive Block Randomization (RABR) design is a viable and advantageous approach for clinical trials.
  • RABR overcomes key limitations of traditional RAR methods, particularly in multi-arm drug development.
  • This design offers improved efficiency and regulatory compliance for adaptive clinical trials.